News Archive

Miracor Medical - New PiCSO Publication

Microvascular dysfunction after successful primary PCI is frequent and contributes to poor outcomes in STEMI.

Read more …

RZNOMICS advance its lead compound, a gene therapy produced using CEVEC's CAP® Ad Technology, into clinical development

CEVEC’s license partner RZNOMICS Inc. receives approval to initiate clinical development of CAP® Ad Technology-produced gene therapy vector in liver cancer patients


Read more …

CryoTherapeutics receives additional funding and launches a new clinical study

CryoTherapeutics, focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks, announces today that it has received additional funding of € 12.3 million.

Read more …

Emperra's EYSYTA in the "Handelsblatt" newspaper

Emperra's digital diabetes management solution ESYSTA among the five trends for the healthcare system of the future in the "Handelsblatt" newspaper:

Click here for the article!

Read more …

Implandata Ophthalmic Products GmbH gewinnt ersten Preis bei der Medizintechnik-Messe Medica

Deutsches Tech-Start-up gewinnt ersten Preis bei der Medica

Auf der Medizintechnik-Messe Medica in Düsseldorf wurden zwei junge Tech-Firmen mit Preisen gewürdigt. Die Start-ups hoffen durch die Auszeichnung auf mehr Sichtbarkeit.


Read more …

CEVEC and UCB sign agreement for the use of CEVEC’s ELEVECTA® AAV manufacturing technology in Gene Therapy

CEVEC Pharmaceuticals GmbH (CEVEC) today announced the signing of an agreement with UCB S.A. (UCB; Euronext: UCB) on the evaluation and use of CEVEC’s proprietary ELEVECTA® Technology for the research, development, and manufacturing of Adeno-Associated Virus (AAV) vectors for gene therapy applications.

Read more …

CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies

CEVEC Pharmaceuticals GmbH (CEVEC), the leading provider of high-performance cell technology for scalable manufacturing of advanced bio-therapeutics, today announced the successful closing of an internal growth financing round.

Read more …

Emperra's digital diabetes management solution ESYSTA now on prescription

Congratulations to our portfolio company Emperra GmbH E-Health Technologies for the listing of their ESYSTA App as the first Diabetes DiGA and becoming the first broadly reimbursed digital diabetes solution in Germany. This is a major achievement and will help many diabetic patients in their daily life.

Read more …